natgillin/translations-raw huggingface dataset:
These findings occurred at exposures below those seen clinically and were largely reversible within 4 weeks of cessation of dosing.
Te spremembe so se pojavile pri izpostavljenostih, ki so bile nižje od klinično opaženih, in so bile v veliki meri reverzibilne v 4 tednih po prenehanju uporabe zdravila.
These findings occurred at plasma concentrations that were below those seen in patients at the 80 mg therapeutic dose.
To so opažali pri plazemskih koncentracijah, nižjih od tistih pri bolnikih, ki prejemajo terapevtski odmerek 80 mg.
These findings should be considered for any child exposed in utero to nucleotide and nucleotide analogues, who presents with severe clinical findings of unknown etiology, particularly neurologic findings.
Te ugotovitve je treba upoštevati pri vseh otrokih, ki so bili in utero izpostavljeni nukleozidnim in nukleotidnim analogom, pri katerih se pojavijo resne klinične ugotovitve neznanega vzroka, še zlasti nevrološke.
These findings should be considered for any child exposed in utero to nucleotide and nucleotide analogues, who presents with severe clinical findings of unknown etiology, particularly neurologic findings..
Te ugotovitve je treba upoštevati pri vseh otrokih, ki so bili in utero izpostavljeni nukleozidnim in nukleotidnim analogom, pri katerih se pojavijo resne klinične ugotovitve neznanega vzroka, še zlasti nevrološke.
These findings were apparent at exposure levels lower than those obtained with clinically recommended doses and were accompanied by maternal toxicities (including ataxia, hypokinesia, tremor and reduced body weight gain).
Ti izsledki so bili opazni pri izpostavljenosti, ki je manjša, kot je dosežena s klinično priporočenimi odmerki; spremljali so jih toksični učinki pri materi (vključno z ataksijo, hipokinezijo, tremorjem in manjšim pridobivanjem telesne mase).
These findings were demonstrated in patients with refractory leukaemia or lymphoma given a dose of 1,500 mg/m2 nelarabine (adults) or a 650 mg/m2 (paediatrics).
Ti podatki so bili pridobljeni pri bolnikih z neodzivno levkemijo ali limfomom, ki so prejemali nelarabin v odmerku 1.500 mg/m2 (odrasli) ali 650 mg/m2 (otroci).
These findings were mainly attributed to rodent-specific vortioxetine-related crystalline material obstruction of the renal tubules and the bile ducts, respectively, and considered of low risk to humans.
Te ugotovitve so predpisali predvsem za glodalce specifični obstrukciji ledvičnih tubulov in žolčevodov zaradi z vortioksetinom povezanega kristaliničnega materiala, in se smatrajo za nizko tveganje za človeka.
These findings were maintained at 48 weeks.
Ti rezultati so bili enaki po 48 tednih.
These findings were mostly mild (Grade 1-2), reversible and not accompanied by clinically significant symptoms that would indicate an impaired liver function.
Zvišanja teh vrednosti so bila večinoma blaga (stopnja 1-2) in reverzibilna, brez klinično pomembnih simptomov, ki bi kazali na okvaro delovanja jeter.
These findings were observed across species at plasma concentrations 4 times the clinical exposure.
Te ugotovitve so potrdila opažanja pri vseh vrstah pri plazemskih koncentracijah  4-kratne plazemske koncentracije pri klinični izpostavitvi.
These findings were observed at doses approximately equivalent to the recommended human dose and were reversible upon termination of administration of panitumumab.
Ti spremembi sta bili po prekinitvi uporabe panitumumaba reverzibilni.
These findings were observed in mice at exposure levels approximately 12-fold the expected human exposure, and in dogs at exposure levels below the expected human exposure.
Te ugotovitve so opažali pri miših, pri stopnjah izpostavljenosti, ki so bile približno 12-krat večje od pričakovane izpostavljenosti pri ljudeh, in pri psih, pri ravneh, ki so bile nižje od pričakovane izpostavljenosti pri ljudeh.
These findings were similar to those observed in the native E. coli L-asparaginase treatment arm.
Ti izsledki so bili podobni kot v skupini, ki je prejemala nativno L-asparaginazo iz E. coli .
These five processes take place in the analyser of a mass spectrometer, which consists of three separate sections: the source, flight tube, and collector.
Teh pet procesov poteka v analizatorju masnega spektrometra, ki je sestavljen iz treh ločenih delov: vira, cevi in detektorja.
These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture.
Ti zlomi se pojavijo po majhni travmi ali brez nje in pri nekaterih bolnikih se pojavi bolečina stegna ali dimelj, pogosto povezana z lastnosti slikanja stresnih zlomov, tedne do mesece pred kompletnim zlomom stegnenice.
These generally occur within the first week of treatment and usually disappear once treatment has stopped.
Večinoma se pojavijo v prvem tednu zdravljenja in po navadi izzvenijo po prekinitvi zdravljenja.
These GI adverse reactions were mostly mild to moderate in severity, with 0.3% of diarrhoea and 0.3% of nausea reported as being severe.
Ti GI neželeni učinki so bili po izraženosti večinoma blagi do zmerni, o hudi driski so poročali v 0,3 % in o hudi navzei prav tako v 0,3 %.
These Grade III rejections occurred in patients with 4 to 6 HLA mismatches (See sections 4.2 and 5.1).
Do zavrnitev stopnje III je prišlo pri bolnikih z neujemanjem HLA 4 do 6 (glejte poglavji 4.2 in 5.1).
These guidelines may not perform similarly when a lead-in treatment with peginterferon alfa and ribavirin has been used prior to starting INCIVO therapy (see section 5.1).
Te smernice morda ne bodo enako učinkovite če se pred uvedbo zdravljenja z zdravilom INCIVO bolnik zdravi s peginterferonom alfa in ribavirinom (glejte poglavje 5.1).
These haematological effects are not usually observed before four to six week’s therapy.
Ti hematološki učinki se navadno ne pojavijo prej kot po štirih do šestih tednih zdravljenja.
These have been generally assessed as non-serious, mild to moderate in severity and self-limiting.
Običajno so bile ocenjene kot neresne, blage do zmerne po resnosti in izzvenijo brez zdravljenja.
These have been identified either from clinical studies or post marketing surveillance.
Odkriti so bili bodisi med kliničnimi študijami ali med spremljanjem v obdobju po začetku trženja zdravila.
These have been reported rarely and may affect up to 1 in 1,000 people taking CELSENTRI.
O teh težavah so poročali redko in se lahko pojavijo pri največ 1 od 1.000 bolnikov, ki jemljejo zdravilo CELSENTRI.
These have generally occurred in patients suffering from advanced malignant diseases, having sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).
Ti primeri so se na splošno pojavili pri bolnikih z napredovalimi malignimi boleznimi, sepso, uporabo več zdravil za kemoterapijo ali zdravljenih z aferezo (glejte poglavje 4.4).
These HCV protease inhibitors are anticipated to be cross-resistant, and co-administration is not recommended (see also section 4.5).
Za te zaviralce HCV proteaze se predvideva, da so navzkrižno odporni, zato se njihova sočasna uporaba ne priporoča (glejte tudi poglavje 4.5).
These hormones are released after a meal and stimulate the pancreas to produce insulin.
Ti se sproščajo po zaužitju hrane in
These hypersensitivity reactions were characterised by rash, fever and sometimes organ involvement (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and eosinophilia) (see section 4.4).
Za te preobčutljivostne reakcije so bili značilni izpuščaj, povišana telesna temperatura in včasih tudi sistemski zapleti (vključevale so, niso pa bile omejene samo na hud izpuščaj ali izpuščaj, ki ga spremljajo zvišana telesna temperatura, slabo počutje, izčrpanost, bolečine v sklepih ali mišicah, izpuščaj z mehurčki, razjede v ustih, konjunktivitis, hepatitis in eozinofilijo) (glejte poglavje 4.4).
These hypoglycaemic events were generally mild in nature.
Ti hipoglikemični dogodki so bili na splošno blagi.
These IgG antibodies appeared to develop following approximately 3-12 months of treatment.
Kaže, da so se ta protitelesa IgG razvila po približno 3-12 mesecih zdravljenja.
These immunosuppressants are not anticipated to affect exposure of efavirenz.
efavirenz, in osebami brez
These improvements were better than those seen with placebo by about 2.7 to 3.7 heavy drinking days a month and about 10 to 18 g of alcohol a day.
Izboljšanja so bila v primerjavi s placebom večja za približno 2,7 do 3,7 dni prekomernega pitja na mesec in za približno 10 do 18 g alkohola na dan.
These improvements were maintained at Week 24.
Ti izboljšanji sta po 24 tednih še vedno trajali.
These improvements were maintained for 52 weeks (Studies 1 and 2).
Navedena izboljšanja so vztrajala 52 tednov (v 1. in 2. študiji).
These improvements were sustained up to Week 48.
Izboljšanja so trajala do 48. tedna.
These improvements were sustained up to Week 52.
Navedeno izboljšanje se je ohranilo do konca 52. tedna.
These improvements were sustained up to Week 52.
Ta izboljšanja so se ohranila do konca 52. tedna.
These include
Obsegajo
These include
Ti ukrepi vključujejo:
These include (but are not limited to):
Ta vključujejo (vendar niso omejena na):
These include acetylsalicylic acid (ASA), P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, and chronic nonsteroidal anti-inflammatory drugs (NSAIDs) (see section 4.5).
Ta zdravila vključujejo acetilsalicilno kislino (ASA), inhibitorje trombocitov P2Y12, druga antitrombotična sredstva, fibrinolitično terapijo in kronična nesteroidna protivnetna zdravila (NSAID) (glejte poglavje 4.5).
These include ATIII-dependent inhibition of other coagulation factors like factor VIIa, induction of endogenous tissue factor pathway inhibitor (TFPI) release as well as a reduced release of von Willebrand factor (vWF) from the vascular endothelium into the blood circulation.
Mednje spada od ATIII odvisno zavrtje drugih koagulacijskih faktorjev, npr. faktorja VIIa, indukcija sproščanja endogenega zaviralca poti tkivnega faktorja (TFPI – tissue factor pathway inhibitor) in zmanjšano sproščanje von Willebrandovega faktorja (vWF) iz žilnega endotelija v krvni obtok.
These include ATIII-dependent inhibition of other coagulation factors like factor VIIa, induction of endogenous tissue factor pathway inhibitor (TFPI) release as well as a reduced release of von Willebrand factor (vWF) from the vascular endothelium into the blood circulation.
Mednje spadajo od ATIII odvisno zavrtje drugih koagulacijskih faktorjev, npr. faktorja VIIa, indukcija sproščanja endogenega zaviralca poti tkivnega faktorja (TFPI – tissue factor pathway inhibitor) in zmanjšano sproščanje von Willebrandovega faktorja (vWF) iz žilnega endotelija v krvni obtok.
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections.
Med slednjimi so skrben izbor darovalcev krvi in plazme, da je zagotovljena izključitev prenašalcev okužb, in preiskovanje vsake darovane enote ter združene plazme za pokazatelje virusov/okužb.
These include Class IA (e.g.quinidine, procainamide, disopyramide) and Class III (e.g. dofetilide, amiodarone) antiarrhythmic agents, citalopram, tricyclic antidepressants, methadone, some antipsychotics (e.g. phenothiazines), fluoroquinolones (e.g. moxifloxacin), some antifungals (e.g. fluconazole, pentamidine), and some antiviral drugs (e.g. telaprevir).
Ta vključujejo antiaritmike razreda IA (npr. kvinidin, prokainamid, dizopiramid) in razreda III (npr. dofetilid, amiodaron), citalopram, triciklične antidepresive, metadon, nekatere antipsihotike (npr. fenotiazini), fluorokinolone (npr. moksifloksacin), nekatere antimikotike (npr. flukonazol, pentamidin) in nekatera protivirusna zdravila (npr. telaprevir).
These include fever, chills, headache, paraesthesia (abnormal sensations like pins and needles), nausea (feeling sick), vomiting and feeling cold.
Neželeni učinki vključujejo povišano telesno temperaturo, glavobol, parestezijo (neobičajne telesne občutke, kot je mravljinčenje), navzejo (občutek slabosti), bruhanje in mrazenje.
These include fever, chills, headaches, pain in the limbs, bone pain and/or feeling generally unwell.
To vključuje zvišano telesno temperaturo, mrzlico, glavobole, bolečino v udih, bolečino v kosteh in/ali splošno slabo počutje.
These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy (see section 5.1).
Ta vključujejo kemoterapijo na osnovi fluoropirimidina, zdravljenje z zaviralci VEGF in zdravljenje z zaviralci EGFR (glejte poglavje 5.1).
These include flushing, fever, chills, headaches and back pain.
Ti vključujejo zardevanje, povišano telesno temperaturo, mrzlico, glavobole in bolečine v hrbtu.
These include infection and Graft-versus host disease (GvHD) which, although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT.
Posledice zajemajo okužbo in reakcija presadka proti gostitelju (GVHD: Graft-versus host disease), ki sta bili, čeprav ne neposredno povezani, glavna vzroka obolevnosti in umrljivosti, zlasti pri alogenski PKMC.
These include loss of co-ordination, problems with ‘saccadic’ (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning difficulties.
Mednje spadajo izguba koordinacije, težave s hitrim, sunkovitim premikanjem oči, ki lahko vodi do okvare vida, zaostalost v razvoju, težave pri požiranju, zmanjšan tonus mišic, krči in težave pri učenju.
These include medicines for the treatment of:
Med njimi so zdravila za zdravljenje:
These include medicines used for abnormal heart rhythm (antiarrhythmics such as quinidine, amiodarone), for depression (citalopram, tricyclic antidepressants), methadone, some antipsychotics (phenothiazines), some antibiotics (fluoroquinolones such as moxifloxacin), some antifungals (fluconazole, pentamidine), and some antiviral drugs (telaprevir).
Med njimi so zdravila, ki se uporabljajo za zdravljenje nenormalnega srčnega ritma (antiaritmiki, kot so kinidin, amiodaron), za zdravljenje depresije (citalopram, triciklični antidepresivi), metadon, nekateri antipsihotiki (fenotiazini), nekateri antibiotiki (fluorokinoloni kot je moksifloksacin), nekateri antimikotiki (flukonazol, pentamidin), in nekatera protivirusna zdravila (telaprevir),
These include medicines used for the treatment of: some antiretroviral medicines used to treat HIV/AIDS and Hepatitis C virus infections (so- called protease inhibitors and non-nucleoside reverse transcriptase inhibitors such asritonavir, nevirapine, efavirenz)
To so lahko naslednja zdravila: nekatera protiretrovirusna zdravila za zdravljenje okužbe z virusom HIV/AIDS in hepatitisa C (imenujemo jih zaviralci proteaze in nenukleozidni zaviralci reverzne transkriptaze, kot so ritonavir, nevirapin in efavirenz)
These include minor haemorrhagic events such as contusion, epistaxis, and petechiae; and major haemorrhagic events, some fatal, including gastrointestinal bleeding, intracranial haemorrhage, and haematuria.
To vključuje manjše hemoragične dogodke, kot so podplutbe, krvavitev iz nosu in petehije, ter večje krvavitve (nekatere so bile smrtne), vključno z gastrointestinalno in intrakranialno krvavitvijo ter hematurijo.
These include other medicines to treat HIV or hepatitis C infection (e.g. atazanavir, cobicistat, darunavir, efavirenz, etravirine, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir), antibiotics (clarithromycin, telithromycin, rifampicin, rifabutin) and antifungal medicines (ketoconazole, itraconazole, fluconazole).
To vključuje druga zdravila za zdravljenje okužbe s HIV ali hepatitisom C (npr. atazanavir, kobicistat, darunavir, efavirenz, etravirin, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, sakvinavir, boceprevir, telaprevir), antibiotike (klaritromicin, telitromicin, rifampicin, rifabutin) in protiglivična zdravila (ketokonazol, itrakonazol, flukonazol).
These include patients with hypokalaemia or hypomagnesaemia, patients with congenital long QT syndrome, patients taking anti-arrhythmic medicinal products or other medicinal products which lead to QT prolongation, and cumulative high dose anthracycline therapy.
Sem so vključeni bolniki s hipokaliemijo ali hipomagneziemijo, bolniki s kongenitalnim sindromom podaljšanega intervala Q-T, bolniki, ki se zdravijo z antiaritmiki ali drugimi zdravili, ki lahko povzročijo podaljšanje intervala Q-T in bolniki, ki se zdravijo z visokimi kumulativnimi odmerki antraciklina.
These include patients:
Med takšne spadajo bolniki:
These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.
Med njimi so dodatki kalija ali nadomestki soli, ki vsebujejo kalij, zdravila, ki varčujejo s kalijem in heparin, zdravila, ki lahko znižajo količino kalija v krvi, kot so diuretiki (tablete za odvajanje vode), kortikosteroidi, odvajala, karbenoksolon, amfotericin ali penicilin G,
These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.
Med njimi so kalijevi nadomestki ali soli, ki vsebujejo kalij, zdravila, ki varčujejo s kalijem in heparin, zdravila, ki lahko znižajo količino kalija v krvi, kot so diuretiki (tablete za odvajanje vode), kortikosteroidi, odvajala, karbenoksolon, amfotericin ali penicilin G,
These include potassium supplements, salt substitutes containing potassium, potassium-sparing medicines and heparin. painkillers of the type called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 (Cox-2) inhibitors.
zdravil, ki zvišujejo koncentracijo kalija v krvi, med katere sodijo nadomestki kalija, nadomestki soli, ki vsebujejo kalij, zdravila, ki varčujejo s kalijem, in heparin. vrste zdravil proti bolečinam, ki jih imenujemo nesteroidna protivnetna zdravila ali selektivni zaviralci ciklooksigenaze-2 (zaviralci COX-2).
These include potassium- sparing diuretics, potassium supplements.
zdravila, ki vam povečajo količino kalija v krvi, med njimi so diuretiki, ki varčujejo s kalijem, in dodatki kalija;
These include potassium- sparing diuretics, potassium supplements.
zdravila, ki vam povečajo količino kalija v krvi, med njimi so diuretiki, ki varčujejo s kalijem, in nadomestki kalija;
These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle, pain on passing urine), headache, flu symptoms and swelling.
Ti vključujejo resne alergijske reakcije (kot sta anafilaksa, angioedem), povišano telesno temperaturo, utrujenost, motnje spanca, bolečine (bolečino v želodcu, bolečino v prsih, bolečino v sklepih ali mišicah, bolečino pri uriniranju), glavobol, gripi podobne simptome in otekline.
These include some antibiotics (Bactrim and Septra used in combination of sulfamethoxazole and trimethoprim), which can be used to treat infections
Med ta zdravila spadajo nekateri antibiotiki (Bactrim in Septra uporabljeni v kombinaciji s sulfametoksazolom in trimetoprimom), ki jih lahko uporabljamo za zdravljenje okužb
These include some antibiotics (Bactrim and Septra used in combination with sulfamethoxole and trimethoprim), which can be used to treat infections
Med ta zdravila spadajo nekateri antibiotiki (Bactrim in Septra uporabljeni v kombinaciji s sulfametoksazolom in trimetoprimom), ki jih lahko uporabljamo za zdravljenje okužb
These include some of the types of medicines used to treat bacterial infections (macrolides [such as erythromycin or clarithromycin] and fluoroquinolones [such as moxifloxacin and sparfloxacin]) or fungal infections (including fluconazole and imidazole) as well as pentamidine (used to treat a specific type of pneumonia) and saquinavir (for treatment of HIV);
Ta vključujejo nekatere vrste zdravil, s katerimi se zdravijo bakterijske okužbe (makrolidi [kot sta eritromicin ali klaritromicin] in fluorokinoloni [kot sta moksifloksacin in sparfloksacin]) ali glivične okužbe (vključno s flukonazolom in imidazolom) ter pentamidin (uporablja se za zdravljenje nekaterih vrst pljučnice) in sakvinavir (za zdravljenje okužbe z virusom HIV);
These include the ADAS-Cog (Alzheimer’s Disease Assessment Scale - Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.).
Med njimi so ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo za kognicijo, ki temelji na storilnosti), CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).
These include the ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.).
Med njimi so ADAS- Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo za kognicijo, ki temelji na storilnosti), CIBIC- Plus (Clinician’s Interview Based Impression of Change-Plus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).